Vioxx was voluntarily withdrawn from the U.S.
market on September 30, 2004 by manufacturer Merck.
The Vioxx market withdrawal was in answer to studies
indicating a higher risk of cardiovascular event in
regular users of Vioxx.
A study on Vioxx (VIGOR study) was published in
2000. It indicated a 4 times increase of risk of
heart attack or stroke in Vioxx (rofecoxib) patients
compared to patients taking naproxen over a 1 year
period. Merck's researchers concluded the
findings of the study showed a protective effect of
naproxen in reducing heart attacks in high
cardiovascular risk patients.
Merck commenced a study (APPROVe study) in 2001 to
evaluate the effects of Vioxx on colorectal polyps.
The study also intended to further evaluate the
cardiovascular risk of Vioxx. The study was
ended early when results showed patients taking Vioxx
were at increased risk of cardiovascular risk compared
to patients taking a placebo after 18 months on the
therapy.
Merck voluntarily withdrew Vioxx from the market on
September 30, 2004 after the APPROVe study was ended
early. In the same month, the FDA also provided
Merck with new research that further supported
increased risk of heart attack among Vioxx users.
Vioxx Market
Withdrawal Best Sellers from
Amazon.com
Poison Pills: The Untold Story of the Vioxx Drug Scandal by Tom Nesi Amazon Price: $3.46
Customer Review: This was a fascinating, excellent book that rather confirms the obvious- pharmaceuticals is BIG BUISINESS-cut throat. And when the CEOs are buisiness men out to make the most money rather then idealists trying to make the world better through medicin...
• Ads Increased Proliferation, Risks Boston Globe
Ads increased proliferation, risksBoston GlobeCHRISTOPH WESTPHAL points out that patients have been deprived of the benefits of Vioxx by its withdrawal from the market. Like other drugs in its class, and more raquo
• FDA Panel: Diabetes Drug Should Stay On Market The Associated Press
FDA panel: Diabetes drug should stay on marketThe Associated PressquotThe two that have been withdrawn for cardiovascular concerns Vioxx and Zelnorm showed three, four or five fold increase in risk,quot Jenkins said.
• Glaxoaposs Settlement Makes The Dividend Safer Probably The Guardian
Glaxo39s settlement makes the dividend safer probablyThe GuardianEver since the generic drug manufacturers upgraded their legal weaponry in the mid 1990s, and especially since the withdrawal of Merck39s Vioxx painkiller in
• Rosiglitazone Hearing Reveals NotSoRosy Rifts At FDA MedPage Today
Rosiglitazone Hearing Reveals Not So Rosy Rifts at FDAMedPage TodayOf the 15 panel members who voted both in 2007 and 2010, only two voted for withdrawal of the drug. Of the 18 panelists who voted only in 2010,
• Avandia On Trial PharmExec.com Blog
PharmExec.com blogAvandia on TrialPharmExec.com blogBoth made their names a decade ago leading the charge against Vioxx, and the Avandia dustup has further burnished their reputations as anti pharma crusaders and more raquo
IMPORTANT
NOTICE:
This webpage is
Copyrighted content. No portion of this page may be copied
to any other webpage, forum, blog or other domain page or
offline publication without written permission from
FactsOfLaw.com. Violators will be prosecuted to the fullest extent of the law.
The information provided by FactsOfLaw.com does not
constitute legal advice or any other type of advice and is
provided for educational purposes only without warranty of any
kind. FactsOfLaw.com has not reviewed the information on this
page for accuracy and is not responsible for any errors,
omissions or inaccuracies. For legal advice you should
consult a licensed attorney.
